TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: dyspnoea
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: periprosthetic bone mineral density changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Scar severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinical complete remission rate of constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median weekly frequency of bowel movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stool consistency (Bristol score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease in the number of sites insensate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in MNSI measures of neuropathic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in pain on the visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the ROC curve (AUC) for CEA trend
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until 50% of the meal had emptied (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postprandial symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Morphine plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in state and trait anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in SAPS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SOD levels before and after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complications per patient
Endpoint domain: Adverse events/effects
Primary endpoint: unplanned intubation
Endpoint domain: Adverse events/effects
Primary endpoint: acute renal failure
Endpoint domain: Adverse events/effects
Primary endpoint: Intradialytic body weight loss to post-dialysis body weight ratio (IBWL/BW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intradialytic plasma volume depletion (IPVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASI 90 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal and Social Performance (PSP) scale total score >70
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Positive and Negative Syndrome Scale (PANSS) total score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in total KHQ scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: percentage density by Cumulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reduction of body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of visceral fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: UDS interpretation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: genital symptoms reported
Endpoint domain: Adverse events/effects
Primary endpoint: new colposcopy findings or findings showing deterioration
Endpoint domain: Adverse events/effects
Primary endpoint: Performance Status (PS) scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total TAD displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCS accuracy in quantifying repolarization changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum level of sedation achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acceptability of buccal midazolam
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median stent function time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity to change in fatigue self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Frequency of PONV
Endpoint domain: Adverse events/effects
Primary endpoint: MMSE decline rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive performance measured by Symbol Digit Modalities Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Surgical intervention rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: offspring's relative fat mass at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TGFβ1 protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protection against influenza vaccine strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency and severity of local and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Baseline fatigue index score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: clinically relevant increases in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak troponin I reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the curve of troponin I over 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of creatine kinase‐myocardial band increases >3 times the upper limit of normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of MRI for detecting MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of MRI for identifying MI location
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower-extremity strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sense of trust in physician
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: time below 37.2 degrees C in four hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change from baseline in the PANNS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of herpes zoster (HZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean absolute change scores on the Mania Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative comfort scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of women having a smear test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of fibrinous complications
Endpoint domain: Adverse events/effects
Primary endpoint: Visual axis obscuration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term incidence of stroke or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: death from all causes
Endpoint domain: Mortality/survival
Primary endpoint: Problem behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete continence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial oxygen desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean serum prolactin concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: EPS as measured by Simpson Scale and Abnormal Involuntary Movement Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of antimanic treatments using valproate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of antimanic treatments using lithium monotherapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CR rate
Endpoint domain: Mortality/survival
Primary endpoint: Response duration rate at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: distal radius BV/TV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FPG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: human plasma total antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined risk of death, worsening heart failure, and life-threatening ventricular tachyarrhythmia
Endpoint domain: Mortality/survival
Primary endpoint: Need for tracheal intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative intensive care admission
Endpoint domain: Adverse events/effects
Primary endpoint: Heart rates and mean arterial pressures intraoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cortical motor excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of resistant E. coli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: NASS results at 12th month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D results at 1st, 6th, and 12th month
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incremental effectiveness measured by QAPFSD
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction in treatment costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean increase of the area of dense breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of applications required for lesion treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypopigmentation
Endpoint domain: Adverse events/effects
Primary endpoint: binary angiographic restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: target vessel revascularization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grade ≥3 treatment-related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in triglycerides (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in HDL cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in LDL cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MACE (Major Adverse Cardiac Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Development of childhood B-cell lymphoma
Endpoint domain: Mortality/survival
Primary endpoint: Basilar maximum blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Degree of atrophy in the affected TGN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial pain evaluation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: radiological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in AUASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in Jenkins sleep scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Self-reported likelihood of prescribing the new drug
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of arm edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement for the assessment of myocardial viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: weaning time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Disclosure of risky behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bone volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STR >70%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Angiographic MVO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DAS28 low activity/remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDAI low activity/remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAPID3 low activity/remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QOL) decline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Non-haematologic Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Atrial action potential durations (APD) prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effective refractory periods (ERP) prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of polymorphic atrial tachyarrhythmias (polyAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response speed and accuracy performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and severity of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: median duration of moist desquamation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinician- and client-perceived severity of toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: prevalence of multidrug-resistant infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Test-retest reliability of PFDI-20, PFIQ-7, QUID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internal consistency of PFDI-20, PFIQ-7, QUID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spanish-English agreement for PFDI-20, PFIQ-7, QUID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovarian hyperstimulation syndrome risk
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in primary care consultations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction in perceived symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Interdental bleeding index (IBI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge from hospital within 6 weeks
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: latency of MEPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: threshold current of MEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: latency of bilateral SSEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: dyspnea NRS at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: erosion resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Circulating serum leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of response defined by increase in platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dyspnea ratings (Borg score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acceptance of Internet-based interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area decrease of wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time from entry into the operating room to discharge home
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Restoration of proximal departments of a hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suboccipital flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SAR test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean bolus consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAPS (Visual Analog Pain Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial contamination rate
Endpoint domain: Adverse events/effects
Primary endpoint: Visual analog scale scores at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevention of leprosy
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in supragingival plaque index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 20% of total GIR-AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum GIR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area of marginal chipping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: calculated gap area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum creatinine concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement of motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rate of digestive tract symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Child-Pugh total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Activity limitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early outcome (death or functional decline)
Endpoint domain: Mortality/survival
Primary endpoint: Rates of Adverse Events Following Immunization (AEFIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Positive conversion rates of hepatitis A vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody levels of HAV-IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of heartburn severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mandibular Aesthetic (MA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chewing Ability (CA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Masticatory Function (MBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in BPRSd
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of p53 and Ras protein expressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Increased necrosis in gastric cancer tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Enhanced proliferation of fibrous tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean supine clinic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean upright clinic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean ambulatory daytime blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: likelihood of achieving remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neointimal coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean neointimal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of malapposed struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SAS (Self-Rating Anxiety Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDS (Self-Rating Depression Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Albumin (Alb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: no limitation in recreational activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 12-hour AUC of FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Asthma-related QOL (total score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life